Abstract
Ixekizumab is a monoclonal antibody targeting interleukin- 17 approved for the treatment of psoriasis. In a recent post hoc meta-analysis of Phase-I t......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
